Title: Cellular Immunotherapy Physician
Company: MWB Consulting
Location: Denver, Colorado, United States
Mark Brunvand, MD, cellular immunotherapy physician at MWB Consulting, has been recognized by Marquis Who’s Who Top Doctors for dedication, achievements, and leadership in health care.
With over four decades of experience, Dr. Brunvand has established a successful career in health care and immunotherapy, specializing in transplantation for hematological malignancies and cellular therapy. He currently excels as a cellular immunotherapy physician and managing medical consulting partner at MWB Consulting LLC, a position he has held since 2022. His experience includes serving as field medical director for CAR T-cell therapy at Bristol Myers Squibb from 2020 to 2023 and as transplant medical director at Cigna from 2017 to 2020. He directed the unrelated donor transplantation program at the Colorado Blood Cancer Institute from 2010 to 2016 and at the Rocky Mountain Cancer Center from 1997 to 2010. He also served as assistant professor of medicine at Oregon Health & Science University and held the role of director of the unrelated donor program from 1995 to 1997. His earlier roles include fellowships at the University of Washington School of Medicine and the National Institute of Allergy and Infectious Diseases, along with residency in internal medicine at the University of Colorado School of Medicine.
Dr. Brunvand has contributed to the field as an author of several publications, including “Final Results of a Phase I Study of the Anti-CD22 Antibody-Drug Conjugate DCDT2980S With or Without Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma” in Blood Journal, “Amyloidosis Relapsing After Autologous Stem Cell Transplantation Treated With Bortezomib” in Haematologica, “Octamer Proteins Inhibit IL-4 Gene Transcription in Normal Human CD4 T Cells” in the Journal of Genes and Immunology, and “Nuclear Factors Interacting With the Mitogen-Responsive Regulatory Region of the Interleukin-2 Gene” in the Journal of Biological Chemistry. He is actively involved in the American Association for the Advancement of Science, the American Society for Blood and Marrow Transplantation, the American Society of Clinical Oncology, the American Society of Hematology, and the American Society of Transplant and Cellular Therapy. Additionally, he is a fellow of the American College of Internal Medicine and has served as a board member for Zen Vault Medical since 2012. Since 2002, he has been an inspector on the Public Relations & Marketing Committee and the Payer Relations Committee for the Foundation for Accreditation of Cellular Therapy and is a founding board member of the Radiation Injury Treatment Network.
He has received numerous awards for his accomplishments, including Patient’s Choice Top Oncologist from 2009 to 2013, the University of Colorado Housestaff Outstanding Teaching Award in 2006, and the Faculty Teaching Award for Outstanding Contributions to Housestaff Education from Oregon Health & Science University in 1996. Additionally, he was honored with the Marion L. Krippaehne Humanism Award in 1996, the American Society of Hematology Scholar Award in 1993, the American Society of Clinical Oncology Young Investigator Award in 1990, and the National Research Service Award from the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases in 1985. He earned his Diplomat of the American Board of Medical Examiners in 1983, followed by Diplomat of the American Board of Internal Medicine in 1985, and Diplomat of the American Board of Medical Oncology in 1989. He also earned a bachelor’s degree in chemistry from Colorado State University in 1978 and a Doctor of Medicine from the University of Colorado School of Medicine in 1982. He completed his residency in Internal Medicine at the University of Colorado in 1985 and pursued a fellowship at the National Institute of Allergy and Infectious Diseases from 1985 to 1988, followed by another fellowship at the University of Washington, Fred Hutchinson Cancer Research Center from 1988 to 1995.
Mr. Brunvand attributes his success to his unwavering passion and his ability to view setbacks as stepping stones rather than roadblocks, believing that every challenge presents an opportunity to refine strategies for optimal results. In coming years, the company he is currently consulting for aims to revolutionize the platform for generating new cellular therapies, representing a significant leap forward in treatment. His goal is to make these groundbreaking therapies accessible to dedicated physicians caring for patients with relapsed and refractory cancer.
Contact Mr. Brunvand:
